BW-20805 / Argo Biopharma - LARVOL DELTA

Hereditary Angioedema Prophylaxis With Prekallikrein siRNA-Phase 1 Safety Outcomes And Prekallikrein Levels (ACAAI 2025) - "Conclusion The Phase 1 study results provide the evidence that BW-20805 is safe and significantly reduces PKK levels in a dose-dependent manner for 24 weeks. This should translate into effective prevention of HAE attacks with convenient dosing intervals potentially extending up to 6 months."

Clinical • P1 data • Cardiovascular • Complement-mediated Rare Disorders • Hereditary Angioedema

HAE: A Phase 2 in Adult Subjects With Hereditary Angioedema (clinicaltrials.gov) - P2 | N=24 | Recruiting | Sponsor: Shanghai Argo Biopharmaceutical Co., Ltd. | Not yet recruiting ➔ Recruiting

Enrollment open • Cardiovascular • Complement-mediated Rare Disorders • Hereditary Angioedema

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BW-20805 in Healthy Subjects (ANZCTR) - P1 | N=32 | Completed | Sponsor: Argo Biopharma Australia Pty Ltd | Recruiting ➔ Completed

Trial completion • Cardiovascular • Complement-mediated Rare Disorders • Hereditary Angioedema

HAE: A Phase 2 in Adult Subjects With Hereditary Angioedema (clinicaltrials.gov) - P2 | N=24 | Not yet recruiting | Sponsor: Shanghai Argo Biopharmaceutical Co., Ltd.

New P2 trial • Cardiovascular • Complement-mediated Rare Disorders • Hereditary Angioedema

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BW-20805 in Healthy Subjects (ANZCTR) - P1 | N=32 | Recruiting | Sponsor: Argo Biopharma Australia Pty Ltd | Not yet recruiting ➔ Recruiting

Enrollment open • Trial initiation date • Cardiovascular • Complement-mediated Rare Disorders • Hereditary Angioedema • IFNG • IL6 • TNFA